Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study.

Manuela di Fusco Xiaowu SunKristen E AllenAlon YehoshuaAlexandra BerkMary B AlvarezThomas M PorterJinma RenLaura PuzniakSantiago M C LopezJoseph Christopher Cappelleri

Published in: Vaccines (2024)

Compared with unvaccinated participants, participants vaccinated with the bivalent were associated with approximately 40% lower risk of long COVID and less symptom burden over the six-month study duration.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
systematic review
respiratory syndrome coronavirus
risk factors